ACY-738 是一种有效的，选择性的，可口服的 HDAC6 抑制剂，IC₅₀ 值为 1.7 nM；ACY-738 同时可抑制 HDAC1，HDAC2 和 HDAC3 的活性，IC₅₀ 值分别为 94，128 和 218 nM。

ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC 50 of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC 50 s of 94, 128, and 218 nM.

Solid

HDAC6 1.7 nM (IC50) HDAC1 94 nM (IC50

ACY-738 (2.5?μM) increases the acetylated (lysine 40) fraction of α-tubulin in RN46A-B14 cells. ACY-738 (10 μM) induces cell death comparable to LBH589 and FK228. has not independently confirmed the accuracy of these methods. They are for reference only.

ACY-738 (5?mg/kg) leads to significant increase in α-tubulin acetylation in whole-brain lysates. ACY-738 (50?mg/kg) fails to produce an enhancement of locomotor activity in WT mice tested in a home cage environment. ACY-738 (5 mg/kg) reaches a maximum plasma concentration of 1310 ng/mL at 0.0830 h following treatment. ACY-738 (5 mg/kg BW) alters BM B cell differentiation, but shows no significant effect on IgG and C3 deposition in NZB/W mice. ACY-738 (20 mg/kg) significantly attenuates the severity of proteinuria in NZB/W F1 mice. ACY-738 (5 mg/kg) shows a significant decrease in anti-dsDNA production in NZB/W mice as they aged. ACY-738 (5, 20 mg/kg) attenuates sera IL-1β production as the NZB/W mice aged. ACY-738 (5 mg/kg) significantly reduces glomerular IL-6 and IL-10 mRNA levels by more than 50% while treatment with 20 mg/kg ACY-738 reduced IL-6 and IL-10 mRNA to non-detec

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Jochems J, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014 Jan;39(2):389-400.
[2]. Regna NL, et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan;162:58-73.

In Vitro: DMSO : ≥ 32 mg/mL (118.39 mM)配制储备液